Register - Pharmaceutical Technology

Pharmaceutical Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X

Advertise with us

Complete Personal Details

First Name*Last Name*Email*Telephone NumberRole In Purchasing*

Job Title*Job Function* Company*Company Activity* Country*

Comments

Optional Data

Email Updates

Please confirm which of the FREE email services you would like to receive from us, you can unsubscribe at any time:

Pharmaceutical Technology Daily Update
preview

Pharmaceutical Technology Weekly Round-up
preview

magazine Pharmaceutical Technology Magazine

Confirmation

Finally, complete a quick security check and confirm terms and conditions:

I have read and accept the terms and conditions and privacy policy.

receive-email We'd like to keep you informed about relevant promotions, products and services, if you would like not to receive these, check this box.

third-party If you would like to hear from carefully selected third party companies, check this box

Clinical Trials

After Zavante deal, Nabriva is poised to launch two first-in-class antibiotics

Fasinumab Phase III osteoarthritis trial meets endpoints

EMA gives PRIME status to promising Huntington’s treatment

Cold Chain

EMA gives PRIME status to promising Huntington’s treatment

UK seeks harmony with EU CTR as NHS and pharma stockpile drugs

Pharma air freight: what does it take to get certified?

Diseases

NUI Galway finds new treatment strategy for breast cancer relapse

BioNTech signs $425m flu vaccine deal with Pfizer

RXi and Karolinska Institutet target solid tumour therapy

Drug Development

So you want to break into the Chinese vaccine market?

Revlimid demonstrates positive phase III results in Indolent NHL

Fasinumab Phase III osteoarthritis trial meets endpoints

Manufacturing

So you want to break into the Chinese vaccine market?

After Zavante deal, Nabriva is poised to launch two first-in-class antibiotics

Big soil: Genentech and Lodo launch $1bn project to develop new drugs from earth

Market Data

So you want to break into the Chinese vaccine market?

Revlimid demonstrates positive phase III results in Indolent NHL

Deals and M&As this week: Aralez Pharmaceuticals, Perrigo, Takeda

Obsessions

Hackers can fool doctors with fake vital signs, but only the rich and powerful need to worry

Human-level intelligent machines will arrive in a decade: Technology industry veteran

UK attempts to plug STEM skills shortage with science visa scheme